Close

Press Releases

PharmaSources Launches the Export-Driven Event CPhI & P-MEC China E-Trade Season

PharmaSources, an international B2B trade portal for the pharmaceutical verticals, is launching the virtual event CPhI & P-MEC China E-Trade Season from August to December 2020. Consisting of the three sessions "Top API Exporters & Products", "Popular Natural Extracts...

Cryoport Expands Global Supply Chain Platform by Signing Agreement to Acquire CRYOPDP

Cryoport, Inc., a global leader in temperature-controlled supply chain solutions for the life sciences industry, announced the expansion of its global supply chain network and services by signing an agreement to acquire CRYOPDP, a leading global provider of innovative...

Pharmaceutical Packaging And Manufacturing Trends To Be Covered By PHARMAP 2021

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2021) will cover the topics of cutting-edge technologies and digitalization in the Manufacturing and Packaging processes of the pharmaceutical industry. It will take place in Berlin, Germany on the 7-8 of June 2021....

Byondis Initiates Phase I Study of Antibody-Drug Conjugate SYD1875

Byondis B.V. (formerly Synthon Biopharmaceuticals B.V.) announced that the first cancer patients have started treatment with its investigational antibody-drug conjugate (ADC) SYD1875. The First-in-Human Dose-Escalation and Expansion Study with the Antibody-Drug Conjugate SYD1875 will evaluate the safety, pharmacokinetics and preliminary...

LANXESS disinfectant kills coronavirus SARS-CoV-2 in just 60 seconds

Rely+On Virkon broad spectrum disinfectant, produced by specialty Chemicals Company LANXESS, demonstrates extremely rapid efficacy against the SARS-CoV-2 virus. This is the finding of a recent study LANXESS commissioned through independent analysis laboratory Microbac Laboratories, Inc. in accordance with the...

Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration

Gilead Sciences, Inc. and Tango Therapeutics announced an expanded strategic collaboration focused on the discovery, development and commercialization of innovative targeted immune evasion therapies for patients with cancer. Under the expanded multi-year collaboration, which builds on an agreement signed in...

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launched to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป